Citius Pharmaceuticals to Participate in Investor Conference
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a prominent biopharmaceutical company, will have its CEO, Leonard Mazur, share important updates and insights during the H.C. Wainwright 26th Annual Global Investment Conference. This event will take place from September 9 to September 11, during which Mr. Mazur will also hold one-on-one meetings with investors.
Details of the Presentation
Mr. Mazur's presentation is set for September 10 at 9:00 am ET. This important session will provide an opportunity to discuss Citius Pharma’s latest advancements and future prospects with potential investors.
Schedule of the Presentation
Those attending will have the chance to engage in an in-depth discussion about Citius's innovations and strategies, led by Mr. Mazur.
Recent Developments at Citius Pharmaceuticals
During his presentation, Mr. Mazur will spotlight several significant advancements within the company, including:
- The recent FDA approval of LYMPHIR™ (denileukin diftitox-cxdl), a groundbreaking treatment for cutaneous T-cell lymphoma (CTCL).
- A strategic merger between one of the Company’s subsidiaries and TenX Keane, resulting in the establishment of Citius Oncology, Inc. (Nasdaq: CTOR), which will strengthen the company’s market position.
- Outcomes from the Phase 3 Pivotal Trial of Mino-Lok, an innovative antibiotic lock solution designed to save central venous catheters from infections.
About Citius Pharmaceuticals
Citius Pharmaceuticals takes pride in being a leader in the development of critical care products. Their thoughtful approach to creating first-in-class therapies demonstrates a strong commitment to addressing urgent healthcare needs. The approval of LYMPHIR is just one milestone in a growing portfolio that also includes products like Mino-Lok and the topical formulation Halo-Lido for hemorrhoidal relief.
Innovative Pipeline
Citius Pharmaceuticals is actively collaborating with the FDA to define future pathways for Mino-Lok and Halo-Lido following successful trial completions in 2023. With ownership stakes in Citius Oncology, the company aims to capitalize on synergies across its diverse therapeutic areas.
Contact Information for Inquiries
Investors seeking more information about Citius can reach out to Ilanit Allen, the key contact for investor relations. Her proactive approach facilitates communication and provides valuable insights into the company's evolving story. Interested individuals can contact her directly by phone.
Frequently Asked Questions
1. What is the focus of the H.C. Wainwright conference?
The conference is designed for companies to showcase their innovations and engage with investors regarding future opportunities and advancements.
2. When will Citius Pharmaceuticals present at the conference?
CEO Leonard Mazur is scheduled to present on September 10 at 9:00 am ET.
3. What key achievements will be discussed by Citius Pharma?
Mr. Mazur will discuss the recent FDA approval of LYMPHIR and the merger with TenX Keane, among other important developments.
4. What products are in Citius Pharmaceuticals' pipeline?
The pipeline includes LYMPHIR for CTCL, Mino-Lok for salvaging catheters, and Halo-Lido for hemorrhoidal relief.
5. How can investors reach Citius Pharmaceuticals?
Investors can contact Ilanit Allen, the investor relations representative, for more information and discussions.
